Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
VF Mautner, R Nguyen, H Kutta, C Fuensterer… - Neuro …, 2010 - academic.oup.com
VF Mautner, R Nguyen, H Kutta, C Fuensterer, C Bokemeyer, C Hagel, RE Friedrich…
Neuro-oncology, 2010•academic.oup.comBilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and
these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the
only established treatment, often damages the vestibular nerve. We report 2 cases in which
treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced
regression of progressive vestibular schwannomas by more than 40% and substantially
improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide …
these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the
only established treatment, often damages the vestibular nerve. We report 2 cases in which
treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced
regression of progressive vestibular schwannomas by more than 40% and substantially
improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide …
Abstract
Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.
Oxford University Press